Humanscape Secures 5 Billion KRW Investment Ahead of IPO

Naver Joins as a New Investor

Digital healthcare company Humanscape announced that it has secured a bridge round investment of 5 billion KRW (approximately 3.8 million USD) following its Series C round. With this investment, Humanscape plans to further solidify its foundation for executing growth strategies and pursuing an initial public offering (IPO) ahead of its planned listing. In September, Humanscape signed an agreement with KB Securities as its lead underwriter and is currently preparing for a KOSDAQ listing. With this latest investment, the company’s cumulative funding has reached 80 billion KRW (approximately 61 million USD).

This round saw Naver join as a new investor, alongside existing investors such as the Singapore branch of Korea Investment Partners and Daewoong Investment, an affiliate of Daewoong Pharmaceutical. Notably, Korea Investment Partners has invested in Humanscape three times, including this round, continuing a long-term growth partnership.

Humanscape currently operates the pregnancy and parenting platform ‘Mamytalk’ and the patient data-based platform ‘RareNote’. ‘Mamytalk’ has become a leading pregnancy and parenting app in Korea by partnering with obstetrics and gynecology clinics to provide ultrasound videos, AI-based growth analysis, and stage-specific information on pregnancy, childbirth, and parenting. The app has also expanded its user base in the United States, Vietnam, and Indonesia, resulting in global revenue tripling year-over-year.

‘RareNote’ provides patients with tailored information such as medical record management, treatment cost calculation, and medication management services. In particular, the disease data accumulated in the field of rare diseases is expected to be utilized for global clinical research and drug development in the future.

The newly raised funds will be primarily used for: ▲expanding into global markets with a focus on the United States; ▲research and development (R&D) of AI healthcare solutions based on patient and platform data; and ▲advancing services through the application of AI technology.

Jang Minhoo, CEO of Humanscape, stated, “Thanks to the efforts of our team members, we have established ourselves as a leading vertical platform in the fields of pregnancy, parenting, and intractable diseases in Korea, and we are achieving successful monetization. We will not settle for domestic achievements but will grow into an influential healthcare company in the global market as well.”